Innovative drug concept stocks
With the continuous increase in global medical and health needs, innovative drugs have become the core driving force for the high-quality development of the pharmaceutical industry. Chinese innovative drug companies are accelerating their move to the international stage, and have made breakthroughs in new drug research and development, clinical trials, commercialization and global cooperation. The Hong Kong stock market has gathered many leading innovative drug companies with independent research and development capabilities, rich pipeline reserves and international competitiveness. This stock list selects representative companies in the field of innovative drugs in Hong Kong stocks, covering multiple treatment fields such as tumors, immunity, and rare diseases, taking into account high-growth targets of platform companies and segmented tracks. We are optimistic about the long-term growth space of innovative drug companies with policy support, technological progress and capital assistance. Through this stock list, investors can lay out the innovative drug industry chain in one stop and seize the structural opportunities in the wave of Chinese pharmaceutical innovation.
RF Trend Master
XtalPi
02228.HK
Innovent Biologics
01801.HK
Conoya-B
02162.HK
Ascletis Pharma
01672.HK
WuXi Partners
02268.HK
Huahao Zhongtian Pharmaceutical-B
02563.HK
Lepu Biopharma-B
02157.HK
Cspc Innovation Pharmaceutical
01093.HK
Kingstar Biotechnology
01548.HK
WuXi AppTec
02359.HK
Innovative drug concept stocks
With the continuous increase in global medical and health needs, innovative drugs have become the core driving force for the high-quality development of the pharmaceutical industry. Chinese innovative drug companies are accelerating their move to the international stage, and have made breakthroughs in new drug research and development, clinical trials, commercialization and global cooperation. The Hong Kong stock market has gathered many leading innovative drug companies with independent research and development capabilities, rich pipeline reserves and international competitiveness. This stock list selects representative companies in the field of innovative drugs in Hong Kong stocks, covering multiple treatment fields such as tumors, immunity, and rare diseases, taking into account high-growth targets of platform companies and segmented tracks. We are optimistic about the long-term growth space of innovative drug companies with policy support, technological progress and capital assistance. Through this stock list, investors can lay out the innovative drug industry chain in one stop and seize the structural opportunities in the wave of Chinese pharmaceutical innovation.
RF Trend Master
Companies(10)
XtalPi
02228.HK
Innovent Biologics
01801.HK
Conoya-B
02162.HK
Ascletis Pharma
01672.HK
WuXi Partners
02268.HK
Huahao Zhongtian Pharmaceutical-B
02563.HK
Lepu Biopharma-B
02157.HK
Cspc Innovation Pharmaceutical
01093.HK
Kingstar Biotechnology
01548.HK
WuXi AppTec
02359.HK
Related Content
© 2025 Rockalpha Limited. All Rights Reserved.
Rockalpha Limited is registered on the New Zealand Financial Service Providers Register(FSP: 1001454). Rockalpha Limited's Financial Service Providers registration can be verified on the Financial Service Providers Register. Rockalpha Limited is a member of the Insurance & Financial Services Ombudsman Scheme, an independent dispute resolution service provider. Rockalpha Limited is not licensed by a New Zealand regulator to provide the client money or property services, and Rockalpha Limited’s registration on the New Zealand register of financial service providers or membership of the Insurance & Financial Services Ombudsman Scheme does not mean that Rockalpha Limited is subject to active regulation or oversight by a New Zealand regulator.Rockalpha Limited is registered on the New Zealand Financial Service Providers Register(FSP: 1001454). Rockalpha Limited's Financial Service Providers registration can be verified on the Financial Service Providers Register. Rockalpha Limited is a member of the Insurance & Financial Services Ombudsman Scheme, an independent dispute resolution service provider.
Rockalpha Limited, operates from its Singapore headquarters at CapitaSky 808, 79 Robinson Road, Singapore 068897, with a regional office at Level 6, Core C, Cyberport 3, 100 Cyberport Road, Hong Kong.